Redx Pharma Plc

Redx Pharma CEO focused on driving fibrosis and oncology assets into the clinic

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), caught up with Proactive London's Andrew Scott to discuss the group's preliminary results to September 2018 as well as the appointment of a new chief financial officer.

Anson says Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Quick facts: Redx Pharma Plc

Price: £0.10

Market: AIM
Market Cap: £12.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...



Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln. The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a...

on 10/7/19

2 min read